Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)
Autore:
Buchler, P; Reber, HA; Buchler, MC; Roth, MA; Buchler, MW; Friess, H; Isacoff, WH; Hines, OJ;
Indirizzi:
Univ Calif Los Angeles, Sch Med, Div Gen Surg, Dept Surg, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 Los Angeles, CA 90095 USA Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA Univ Calif Los Angeles Los Angeles CA USA 90024 Los Angeles, CA 90024 USA Univ Bern, Inselspital, CH-3010 Bern, Switzerland Univ Bern Bern Switzerland CH-3010 nselspital, CH-3010 Bern, Switzerland
Titolo Testata:
JOURNAL OF GASTROINTESTINAL SURGERY
fascicolo: 2, volume: 5, anno: 2001,
pagine: 139 - 146
SICI:
1091-255X(200103/04)5:2<139:TFPCWA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTATIC BREAST-CANCER; RECEPTOR-ENHANCED CHEMOSENSITIVITY; MONOCLONAL-ANTIBODY; GROWTH-FACTORS; HER-2/NEU; CARCINOMA; ONCOGENE; ADENOCARCINOMA; AMPLIFICATION; EXPRESSION;
Keywords:
pancreatic cancer; herceptin; treatment; HER2/neu; animal model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Hines, OJ Univ Calif Los Angeles, Sch Med, Div Gen Surg, Dept Surg, 72-215CHS,10833Le Conte Ave, Los Angeles, CA 90095 USA Univ Calif Los Angeles 72-215 CHS,10833 Le Conte Ave Los Angeles CA USA 90095
Citazione:
P. Buchler et al., "Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)", J GASTRO S, 5(2), 2001, pp. 139-146

Abstract

The HER2/neu oncogene is overexpressed in human pancreatic cancer, but theclinical significance of that overexpression is uncertain. In the present study we investigated the antitumor efficacy of Herceptin, a new recombinant humanized anti-HER2/neu antibody, which exhibits cytostatic activity on breast and prostate cancer cells that overexpress the HER2 oncogene. That antibody may retard tumor growth in certain patients with those diseases. We quantified HER2 expression in various human pancreatic cancer cell lines and studied the bioactivity of this antibody both in vitro and in vivo. Growth inhibition by Herceptin was observed in vitro in cell lines with high levels of HER2/neu expression. Cell lines with low levels of this protein did not respond significantly to the antibody In vivo we studied two different pancreatic cancer cell lines in an orthotopic mouse model of the disease. Herceptin treatment suppressed tumor growth in the MIA PaCa-2 tumor cell line, which expressed high levels of HER2/neu. These data suggest that Herceptin treatment of patients with pancreatic cancer who express high levels of the I HER2/neu oncogene may be reasonable.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 11:52:54